(Reuters) – Staff reviewers at the U.S. Food and Drug Administration identified several uncertainties with Veru Inc’s data for oral COVID-19 pill for treating moderate-to-severe hospitalized patients at high risk of developing an acute respiratory distress syndrome, according to briefing documents published on Monday.
(Reporting by Bhanvi Satija and Raghav Mahobe in Bengaluru; Editing by Shinjini Ganguli)
